Clinical Trial Update: A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

View source ↗

Summary

A long-term registry update on the use of Humira (adalimumab) for patients with moderately to severely active ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: AbbVie | Conditions: Ulcerative Colitis (UC) | Status: ACTIVE_NOT_RECRUITING